Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KALEXATE vs TIGLUTIK KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.
Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs),Treatment of giant cell arteritis in adult patients
Amyotrophic lateral sclerosis (ALS)
10 mg orally once daily.
50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/m L oral suspension packet with 10 m L of water.
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Terminal elimination half-life is approximately 9-15 hours, with a mean of 12 hours. Steady-state is reached within 5-7 days. Clinically, this supports twice-daily dosing.
KALEXATE is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes or pathways are involved.
Hepatic metabolism primarily via CYP1A2, with minor contributions from CYP3A4 and glucuronidation.
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Riluzole is primarily eliminated via hepatic metabolism, with <10% excreted unchanged in urine. Metabolites are eliminated renally (~85%) and fecally (~5%).
60-70% primarily to albumin
97% bound primarily to plasma proteins, including albumin and lipoproteins.
1.2-1.6 L/kg; indicates extensive extravascular distribution
Approximately 3.4 L/kg, indicating extensive tissue distribution, particularly into the CNS.
Oral: 85-95%
Oral bioavailability is approximately 60% (range 36-76%) due to extensive first-pass metabolism. High-fat meals reduce AUC by 20% and Cmax by 45%.
GFR >= 60 m L/min: no adjustment; GFR < 60 m L/min: use not recommended.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B), but use with caution.
Not approved for pediatric use.
Not approved for pediatric patients under 18 years of age. Safety and efficacy have not been established.
No specific dose adjustment; monitor renal function.
No specific dose adjustment recommended based on age alone; consider renal function and overall frailty. Monitor for adverse effects, particularly falls and dysphagia.
Risk of serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients should be screened for latent tuberculosis prior to initiation. If serious infection develops, interrupt KALEXATE until infection is controlled.
None
Serious infections,Hepatotoxicity (elevated liver enzymes),Neutropenia,Thrombocytopenia,Lipid elevations,Gastrointestinal perforation (risk higher in patients with diverticulitis),Hypersensitivity reactions,Live vaccines should not be given concurrently
Hepatic injury (elevated transaminases, bilirubin),Neutropenia,Interstitial lung disease,Dizziness and somnolence
Known hypersensitivity to KALEXATE or any of its excipients,Active infections including localized infections
Hypersensitivity to riluzole or any component of the formulation,Concomitant use with tizanidine,Severe hepatic impairment (Child-Pugh class C)
Avoid potassium-rich foods (bananas, oranges, potatoes, spinach, tomatoes, salt substitutes). Do not mix with fruit juices containing high potassium (e.g., orange, tomato). Maintain adequate fluid intake to prevent constipation.
Avoid high-fat meals (e.g., fried foods, cheese, creamy sauces) within 1 hour before or 2 hours after dosing, as they increase absorption and may increase risk of side effects. Grapefruit juice may increase riluzole levels; avoid concurrent consumption.
Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypernatremia) may indirectly affect fetal development. No specific teratogenic risk is documented; avoid severe maternal electrolyte imbalances.
FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefit justifies risk. Second/third trimesters: possible fetal growth restriction; avoid if possible.
Kalexate is not absorbed from the gastrointestinal tract, so systemic concentrations are negligible. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte imbalance if maternal use is prolonged.
Excretion into human milk unknown; M/P ratio not established. Caution advised; consider discontinuing nursing or drug based on importance to mother.
Standard dosing (15-60 g orally per day) may be used in pregnancy. No pharmacokinetic changes requiring dose adjustment as the drug is not absorbed. However, monitor electrolytes more frequently due to pregnancy-related volume expansion and altered renal function.
No standard dose adjustments established; pharmacokinetics in pregnancy not studied; monitor clinical response and adjust based on tolerability.
Kalexate (sodium polystyrene sulfonate) exchanges sodium for potassium in the gastrointestinal tract. Onset of action is 2-12 hours. Avoid in patients with hypokalemia, severe hypernatremia, or bowel obstruction. Monitor serum potassium and sodium levels regularly. Use with caution in patients with congestive heart failure or severe edema due to sodium load. Administer orally or as a retention enema; do not mix with fruit juices containing high potassium (e.g., orange juice).
Tiglutik (riluzole) is the first liquid formulation of riluzole, approved for ALS. It can be administered via feeding tube. Monitor liver function tests (ALT, AST) monthly for 3 months, then quarterly. Avoid use in patients with baseline transaminase elevations >3x ULN. Concomitant use with hepatotoxic drugs (e.g., NSAIDs, acetaminophen >3 g/day) requires caution. Has a high fat emulsion suspension; do not dilute.
Take this medication exactly as prescribed to lower high potassium levels.,Do not mix with orange juice or other high-potassium beverages.,Drink plenty of water with each dose to prevent constipation.,Report any signs of bowel obstruction (severe abdominal pain, vomiting, no bowel movements) immediately.,Notify your doctor if you experience irregular heartbeat, muscle weakness, or numbness/tingling.,This medication contains sodium; inform your doctor if you have heart failure or high blood pressure.
Take each dose at least 1 hour before or 2 hours after a meal to avoid food interactions.,Shake the bottle well for at least 30 seconds before each use.,Use the provided dosing syringe to measure the correct dose; do not use household spoons.,If you miss a dose, take it as soon as you remember unless it is close to the next dose; do not double-dose.,Report any yellowing of skin or eyes, dark urine, or abdominal pain immediately as signs of liver toxicity.,You may feel dizzy or lightheaded; avoid driving until you know how the drug affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KALEXATE vs TIGLUTIK KIT, answered by our medical review team.
KALEXATE is a SSRI Antidepressant that works by KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.. TIGLUTIK KIT is a Amyotrophic Lateral Sclerosis Agent that works by Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KALEXATE and TIGLUTIK KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KALEXATE is: 10 mg orally once daily.. The standard adult dose of TIGLUTIK KIT is: 50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/m L oral suspension packet with 10 m L of water.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KALEXATE and TIGLUTIK KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KALEXATE is classified as Category C. Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypern. TIGLUTIK KIT is classified as Category C. FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.